Calcitonin inhalation - Inhale Therapeutic Systems

Drug Profile

Calcitonin inhalation - Inhale Therapeutic Systems

Alternative Names: Calcitonin aerosol - Inhale Therapeutic Systems; Salcatonin aerosol - Inhale Therapeutic Systems; Salcatonin inhalation - Inhale Therapeutic Systems

Latest Information Update: 27 Nov 2006

Price : $50

At a glance

  • Originator Nektar Therapeutics
  • Class
  • Mechanism of Action Calcitonin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bone disorders; Hypercalcaemia; Osteitis deformans; Postmenopausal osteoporosis

Most Recent Events

  • 10 Nov 2000 No-Development-Reported for Bone disorders in United Kingdom (Inhalation)
  • 10 Nov 2000 No-Development-Reported for Hypercalcaemia in United Kingdom (Inhalation)
  • 10 Nov 2000 No-Development-Reported for Osteitis deformans in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top